A review on guidelines for management and treatment of common variable immunodeficiency

Expert Rev Clin Immunol. 2013 Jun;9(6):561-74; quiz 575. doi: 10.1586/eci.13.30.

Abstract

Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency in adults. As symptoms of CVID are usually heterogeneous and unspecific, diagnosis and follow-up of CVID can be challenging. In light of this, a broad review of advances in management and treatment of CVID is performed here in order to reach a distinct protocol. However, it should be noted that owing to the nature of the disease, it can only be treated symptomatically but not cured. There is little evidence to guide appropriate or universal guidelines to improve the current status of management of the disease. The most satisfactory treatments of CVID could be achieved by the use of immunoglobulin replacement, antibiotics, immunosuppressants and hematopoietic stem cell transplantation. This review is written based on the importance of clinical surveillance of asymptomatic CVID cases and early recognition of different clinical complications. Moreover, for each complication, appropriate interventions for improving outcomes are mentioned.

Publication types

  • Review

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Common Variable Immunodeficiency / diagnosis
  • Common Variable Immunodeficiency / immunology
  • Common Variable Immunodeficiency / pathology
  • Common Variable Immunodeficiency / therapy*
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Practice Guidelines as Topic

Substances

  • Anti-Bacterial Agents
  • Immunosuppressive Agents